Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic

14Citations
Citations of this article
138Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The recent empirical use of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID-19) revived the interest in its cardiac toxicity, increasingly sidelined over time. We aimed to assess and compare the profile of cardiac adverse drug reactions (CADRs) associated with HCQ before and during COVID-19. We performed a retrospective comparative observational study using the French Pharmacovigilance network database between 1985 and May 2020 to assess all postmarketing CADRs associated with HCQ notified before COVID-19 in its approved indications for lupus and rheumatoid arthritis (preCOV), and those concerning its empirical use in COVID-19 (COV). Eighty-five CADR in preCOV were compared with 141 CADRs in COV. The most common CADR of preCOV were cardiomyopathies (42.4%) and conduction disorders (28.2%), both statistically more frequent than in COV (P < 0.001). COV notifications significantly highlighted repolarization and ventricular rhythm disorders (78.0%, P < 0.001) as well as sinus bradycardias (14.9%, P = 0.01) as compared with preCOV. Estimated incidence of CADR was significantly higher among patients exposed to off-label use of HCQ in COVID-19 (2.9%) than before COVID-19 in its approved indications (0.01%, P < 0.001). The use of HCQ in COVID-19 sheds a new light on the spectrum of its cardiac toxicity. This fosters the value of a closer monitoring of all patients treated with HCQ, regardless of its indication, and the importance of an update of its summary of product characteristics.

References Powered by Scopus

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

2060Citations
N/AReaders
Get full text

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2030Citations
N/AReaders
Get full text

2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus

1481Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

14Citations
N/AReaders
Get full text

Drug-induced cardiac toxicity and adverse drug reactions, a narrative review

11Citations
N/AReaders
Get full text

Characteristics of bradyarrhythmia in patients with COVID-19: Systematic scoping review

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Romani, S., Gérard, A., Fresse, A., Viard, D., Van-Obberghen, É., Micallef, J., … Drici, M. D. (2021). Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. Clinical and Translational Science, 14(1), 163–169. https://doi.org/10.1111/cts.12883

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

58%

Researcher 6

25%

Professor / Associate Prof. 2

8%

Lecturer / Post doc 2

8%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 24

44%

Medicine and Dentistry 17

31%

Biochemistry, Genetics and Molecular Bi... 9

17%

Agricultural and Biological Sciences 4

7%

Save time finding and organizing research with Mendeley

Sign up for free